Last $0.05 USD
Change Today 0.00 / 0.00%
Volume 0.0
QRXPY On Other Exchanges
Symbol
Exchange
Berlin
OTC US
OTC US
As of 8:10 PM 02/20/15 All times are local (Market data is delayed by at least 15 minutes).

qrxpharma ltd-sponsored adr (QRXPY) Snapshot

Open
$0.05
Previous Close
$0.05
Day High
$0.05
Day Low
$0.05
52 Week High
03/21/14 - $4.35
52 Week Low
11/13/14 - $0.05
Market Cap
1.7M
Average Volume 10 Days
305.0
EPS TTM
--
Shares Outstanding
32.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for QRXPHARMA LTD-SPONSORED ADR (QRXPY)

Related News

No related news articles were found.

qrxpharma ltd-sponsored adr (QRXPY) Related Businessweek News

No Related Businessweek News Found

qrxpharma ltd-sponsored adr (QRXPY) Details

QRxPharma Limited develops and commercializes biopharmaceutical products primarily in Australia. It develops proprietary Dual Opioid formulations for treating patients with moderate to severe acute or chronic pain. The company develops pain management products consisting of Moxduo Immediate Release, an oral capsule for the treatment of moderate to severe acute pain; Moxduo Controlled Release oral tablet for chronic pain; and Moxduo Intravenous formulation for hospital-based, post-surgical pain, as well as Pro-drug/Hybrid Dual Opioids. It also offers abuse prevention products, including Stealth Beadlets abuse deterrent technology. QRxPharma Limited is based in North Sydney, Australia.

qrxpharma ltd-sponsored adr (QRXPY) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$441.2K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$262.8K
Senior Vice President of Global Business Deve...
Total Annual Compensation: A$326.6K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: A$65.1K
Compensation as of Fiscal Year 2014.

qrxpharma ltd-sponsored adr (QRXPY) Key Developments

QRxPharma Limited Reports Consolidated Earnings Results for the Half-Year Ended December 31, 2014

QRxPharma Limited reported consolidated earnings results for the half-year ended December 31, 2014. For the period, the company reported loss from continuing operations and net loss attributable to owners of the company of AUD 4.7 million or 2.9 cents per basic and diluted share compared to a net loss of AUD 5.1 million or 3.5 cents per basic and diluted share for the half-year ended December 31, 2013. The company reported revenue from continuing operations of AUD 6,000 compared to AUD 620,000, loss before income tax of AUD 4,737,000 compared to AUD 5,132,000, net cash outflow from operating activities of AUD 5,122,000 compared to AUD 5,962,000 and payments for property, plant and equipment payments for property, plant and equipment of AUD 7,000 compared to AUD 60,000 for the last year.

QRxPharma Limited Reports Preliminary Earnings Results for the Financial Year Ended June 30, 2014

QRxPharma Limited reported preliminary earnings results for the financial year ended June 30, 2014. For the year, the company's revenue from ordinary activities was down 84% to AUD 670,000. Net loss from ordinary activities after tax attributable to members was up 32% to AUD 13,335,000. Net loss from ordinary activities The net loss of AUD 13.3 million against net loss AUD 10.1 million a year ago, resulted from the group's continuing efforts to secure approval for immediate release Moxduo(R), a Dual Opioid(R), for the treatment of moderate to severe acute pain. The net loss includes Research and development expenditure of AUD 6.0 million against AUD 8.3 million in 2013 which includes AUD 3.7 million against AUD 4.4 million in 2013 for clinical and regulatory activities associated with the progression of the NDA for immediate release Moxduo with the FDA, including preparation for the FDA Advisory Committee together with advancing the regulatory filings in Europe, Australia and Canada; with a decrease in spend on product and manufacturing process development to AUD 1.2 million against AUD 2.9 million in 2013.

QRxPharma Limited Announces Board Changes

QRxPharma Limited announced that Chairman, Dr. Peter Farrell and Director, Dr. Gary Pace have resigned from the QRxPharma board effective at 9:50 am (AEST) 9 July 2014 prior to commencement of the General Meeting (GM) requisitioned by shareholders associated with Langley Walker. It is expected that Bruce Hancox and Dr. Richard Treagus will be appointed as directors pursuant to resolutions in the requisitioned notice of meeting, with those appointments taking effect from the close of the meeting. The Company also announced that directors Peter Campbell and Michael Quinn have tendered their resignations from the QRxPharma board.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QRXPY:US $0.05 USD 0.00

QRXPY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QRXPY.
View Industry Companies
 

Industry Analysis

QRXPY

Industry Average

Valuation QRXPY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.7x
Price/Book 0.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QRXPHARMA LTD-SPONSORED ADR, please visit www.qrxpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.